Case number 1:23-cv-00137
Exela Pharma Sciences, LLC v. Hikma Pharmaceuticals USA Inc. > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jun 30, 2023 | 50 | [SEALED] STIPULATION of Dismissal by Exela Pharma Sciences, LLC. (Booker, Gregory) (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 51 | [SEALED] SO ORDERED re 50 Stipulation of Dismissal. ***Civil Case Terminated. Signed by Judge Maryellen Noreika on 6/30/2023. This order has been emailed to local counsel. (dlw) (Entered: 06/30/2023) (0) |
| Jun 16, 2023 | 49 | STIPULATION TO EXTEND TIME to Respond to Plaintiff Exela Pharma Sciences, LLC's Complaint to June 30, 2023 - filed by Hikma Pharmaceuticals USA Inc.. (Weinblatt, Richard) (Entered: 06/16/2023) (2) |
| Jun 16, 2023 | N/A | SO ORDERED re 49 STIPULATION TO EXTEND TIME to Respond to Plaintiff Exela Pharma Sciences, LLC's Complaint to June 30, 2023 (Set/Reset Answer Deadlines: Hikma Pharmaceuticals USA Inc. answer due 6/30/2023). ORDERED by Judge Maryellen Noreika on 6/16/2023. (dlw) (Entered: 06/16/2023) (0) |
| May 16, 2023 | N/A | SO ORDERED re 48 STIPULATION TO EXTEND TIME to respond to Plaintiff Exela Pharma Sciences, LLC's Complaint to June 16, 2023 (Set/Reset Answer Deadlines: Hikma Pharmaceuticals USA Inc. answer due 6/16/2023). ORDERED by Judge Maryellen Noreika on 5/16/2023. (dlw) (Entered: 05/16/2023) (0) |
| May 15, 2023 | 48 | STIPULATION TO EXTEND TIME to respond to Plaintiff Exela Pharma Sciences, LLC's Complaint to June 16, 2023 - filed by Hikma Pharmaceuticals USA Inc.. (Weinblatt, Richard) (Entered: 05/15/2023) (2) |
| May 8, 2023 | N/A | Pro Hac Vice Attorney Charles B. Klein for Hikma Pharmaceuticals USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 05/08/2023) (0) |
| May 4, 2023 | 47 | NOTICE requesting Clerk to remove Shashank Upadhye, Yixin Tang, and Brent Batzer as co-counsel. Reason for request: withdrawal of appearance. (Weinblatt, Richard) (Entered: 05/04/2023) (2) |
| May 3, 2023 | N/A | Pro Hac Vice Attorney Jovial Wong for Hikma Pharmaceuticals USA Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (jdb) (Entered: 05/03/2023) (0) |
| May 1, 2023 | N/A | SO ORDERED re 46 MOTION for Pro Hac Vice Appearance of Attorney Charles B. Klein, Jovial Wong, and Claire A. Fundakowski filed by Hikma Pharmaceuticals USA Inc. ORDERED by Judge Maryellen Noreika on 5/1/2023. (dlw) (Entered: 05/01/2023) (0) |
| Apr 28, 2023 | 46 | MOTION for Pro Hac Vice Appearance of Attorney Charles B. Klein, Jovial Wong, and Claire A. Fundakowski - filed by Hikma Pharmaceuticals USA Inc.. (Weinblatt, Richard) (Entered: 04/28/2023) (6) |
| Apr 27, 2023 | 44 | SO ORDERED re 42 Unopposed MOTION to Substitute Party: Hikma Pharmaceuticals USA Inc. to replace Nivagen Pharmaceuticals, Inc. Signed by Judge Maryellen Noreika on 4/27/2023. (dlw) (Entered: 04/27/2023) (2) |
| Apr 27, 2023 | 45 | STIPULATED PROTECTIVE ORDER. Signed by Judge Maryellen Noreika on 4/27/2023. (dlw) (Entered: 04/27/2023) (19) |
| Apr 26, 2023 | 42 | Unopposed MOTION to Substitute Party: Hikma Pharmaceuticals USA Inc. to replace Nivagen Pharmaceuticals, Inc. - filed by Nivagen Pharmaceuticals, Inc., Hikma Pharmaceuticals USA Inc.. (Weinblatt, Richard) (Entered: 04/26/2023) (3) |
| Apr 26, 2023 | 43 | PROPOSED ORDER [Proposed] Stipulated Protective Order by Hikma Pharmaceuticals USA Inc.. (Weinblatt, Richard) (Entered: 04/26/2023) (19) |
| Apr 18, 2023 | N/A | SO ORDERED re 41 STIPULATION TO EXTEND TIME for Nivagen Pharmaceuticals Inc. to move, answer, or otherwise respond to the Complaint to May 17, 2023 (Set/Reset Answer Deadlines: Nivagen Pharmaceuticals, Inc. answer due 5/17/2023). ORDERED by Judge Maryellen Noreika on 4/18/2023. (dlw) (Entered: 04/18/2023) (0) |
| Apr 17, 2023 | 41 | STIPULATION TO EXTEND TIME for Nivagen Pharmaceuticals Inc. to Respond to Complaint to May 17, 2023 - filed by Nivagen Pharmaceuticals, Inc.. (Weinblatt, Richard) (Entered: 04/17/2023) (3) |
| Apr 12, 2023 | 39 | [SEALED] Transcript of Teleconference held on 03/03/2023 before Judge Maryellen Noreika.. (dh) (Entered: 04/12/2023) (0) |
| Apr 12, 2023 | 40 | Redaction of 39 Transcript. (dh) (Entered: 04/12/2023) (0) |
| Apr 10, 2023 | N/A | SO ORDERED re 38 STIPULATION TO EXTEND TIME to File Answer to April 17, 2023 (Set/Reset Answer Deadlines: Nivagen Pharmaceuticals, Inc. answer due 4/17/2023). ORDERED by Judge Maryellen Noreika on 4/10/2023. (dlw) (Entered: 04/10/2023) (0) |
| Apr 6, 2023 | 38 | STIPULATION TO EXTEND TIME to File Answer to April 17, 2023 - filed by Nivagen Pharmaceuticals, Inc.. (Weinblatt, Richard) (Entered: 04/06/2023) (2) |
| Mar 29, 2023 | 37 | STIPULATED PROTECTIVE ORDER. Signed by Judge Maryellen Noreika on 3/29/2023. (dlw) (Main Document 37 replaced on 3/29/2023) (dlw). (Entered: 03/29/2023) (19) |
| Mar 28, 2023 | 36 | PROPOSED ORDER // Stipulated Protective Order by Exela Pharma Sciences, LLC. (Booker, Gregory) Modified on 3/29/2023 (dlw). (Entered: 03/28/2023) (19) |
| Mar 27, 2023 | 33 | Proposed STIPULATION Regarding Scheduling for Preliminary Injunction Proceeding by Exela Pharma Sciences, LLC. (Booker, Gregory) (Entered: 03/27/2023) (3) |
| Mar 27, 2023 | 34 | SO ORDERED re 33 Stipulation and Order Regarding Scheduling for Preliminary Injunction Proceedings. Signed by Judge Maryellen Noreika on 3/27/2023. (dlw) (Entered: 03/27/2023) (3) |
| Mar 27, 2023 | 35 | NOTICE OF SERVICE of Plaintiff's Initial Infringement Contentions and Claim Chart filed by Exela Pharma Sciences, LLC.(Booker, Gregory) (Entered: 03/27/2023) (2) |
| Mar 10, 2023 | 31 | Letter to Honorable Maryellen Noreika from Gregory R. Booker regarding status of issues addressed at hearing. (Booker, Gregory) (Entered: 03/10/2023) (2) |
| Mar 10, 2023 | 32 | REDACTED VERSION of 27 Letter by Nivagen Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) (Entered: 03/10/2023) (Main Document) (3) |
| Mar 10, 2023 | 32 | REDACTED VERSION of 27 Letter by Nivagen Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) (Entered: 03/10/2023) (Exhibit A) (7) |
| Mar 10, 2023 | 32 | REDACTED VERSION of 27 Letter by Nivagen Pharmaceuticals, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Stamoulis, Stamatios) (Entered: 03/10/2023) (Exhibit B) (6) |
| Mar 9, 2023 | 30 | REDACTED VERSION of 28 Letter by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Booker, Gregory) (Entered: 03/09/2023) (Main Document) (3) |
| Mar 9, 2023 | 30 | REDACTED VERSION of 28 Letter by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Booker, Gregory) (Entered: 03/09/2023) (Exhibit 1) (2) |
| Mar 9, 2023 | 30 | REDACTED VERSION of 28 Letter by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Booker, Gregory) (Entered: 03/09/2023) (Exhibit 2) (3) |
| Mar 9, 2023 | 30 | REDACTED VERSION of 28 Letter by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Booker, Gregory) (Entered: 03/09/2023) (Exhibit 3) (7) |
| Mar 3, 2023 | N/A | Minute Entry for proceedings held before Judge Maryellen Noreika - Telephone Conference held on 3/3/2023 re Letters ( 27 , 28 ). The parties shall discuss the issues further and submit a proposed schedule moving forward after those discussions have concluded. (Court Reporter Dale Hawkins.) (mdb) (Entered: 03/03/2023) (0) |
| Mar 2, 2023 | 28 | [SEALED] Letter to Honorable Maryellen Noreika from Gregory R. Booker regarding response to Nivagen letter regarding relief - re 27 Letter. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Booker, Gregory) (Entered: 03/02/2023) (0) |
| Mar 2, 2023 | 29 | ORAL ORDER Setting Teleconference re 27 28 Letters - IT IS HEREBY ORDERED that a Telephone Conference is set for 3/3/2023 at 10:00 AM before Judge Maryellen Noreika. Counsel shall provide a teleconference dial-in number and code for the teleconference by emailing this Court's judicial administrator. ORDERED by Judge Maryellen Noreika on 3/2/2023. (dlw) (Entered: 03/02/2023) (0) |
| Mar 1, 2023 | 27 | [SEALED] Letter to The Honorable Maryellen Noreika from Richard C. Weinblatt regarding Relief from the February 8, 2023 Order - re Telephone Conference,, Terminate Motions,. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Weinblatt, Richard) (Entered: 03/01/2023) (0) |
| Feb 22, 2023 | N/A | SO ORDERED re 26 STIPULATION TO EXTEND TIME to Answer the Complaint to April 10, 2023 (Set/Reset Answer Deadlines: Nivagen Pharmaceuticals, Inc. answer due 4/10/2023). ORDERED by Judge Maryellen Noreika on 2/22/2023. (dlw) (Entered: 02/22/2023) (0) |
| Feb 21, 2023 | 26 | STIPULATION TO EXTEND TIME to Answer the Complaint to April 10, 2023 - filed by Nivagen Pharmaceuticals, Inc.. (Weinblatt, Richard) (Entered: 02/21/2023) (2) |
| Feb 15, 2023 | N/A | Pro Hac Vice Attorney Yixin Tang for Nivagen Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/15/2023) (0) |
| Feb 15, 2023 | N/A | Pro Hac Vice Attorney Brent A. Batzer for Nivagen Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/15/2023) (0) |
| Feb 15, 2023 | 25 | Letter to Honorable Maryellen Noreika from Gregory R. Booker regarding Status Report. (Booker, Gregory) (Entered: 02/15/2023) (1) |
| Feb 14, 2023 | N/A | Pro Hac Vice Attorney Shashank D. Upadhye for Nivagen Pharmaceuticals, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/14/2023) (0) |
| Feb 13, 2023 | N/A | SO ORDERED re 22 MOTION for Pro Hac Vice Appearance of Attorney Shashank Upadhye, Yixin Tang, and Brent Batzer filed by Nivagen Pharmaceuticals, Inc. ORDERED by Judge Maryellen Noreika on 2/13/2023. (dlw) (Entered: 02/13/2023) (0) |
| Feb 13, 2023 | 23 | REDACTED VERSION of 9 Opening Brief in Support, by Exela Pharma Sciences, LLC. (Sundermeir, Grayson) (Entered: 02/13/2023) (25) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Main Document) (3) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 1) (30) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 2) (8) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 3) (5) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 4) (6) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 5) (10) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 6) (8) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 7) (3) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 8) (30) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 9) (24) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 10) (28) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 11) (5) |
| Feb 13, 2023 | 24 | REDACTED VERSION of 10 Declaration by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9, # 10 Exhibit 10, # 11 Exhibit 11, # 12 Exhibit 12)(Sundermeir, Grayson) Modified on 2/13/2023 (dlw). (Entered: 02/13/2023) (Exhibit 12) (9) |
| Feb 10, 2023 | 20 | NOTICE of Appearance by Richard Charles Weinblatt on behalf of Nivagen Pharmaceuticals, Inc. (Weinblatt, Richard) (Entered: 02/10/2023) (1) |
| Feb 10, 2023 | 21 | NOTICE of Appearance by Stamatios Stamoulis on behalf of Nivagen Pharmaceuticals, Inc. (Stamoulis, Stamatios) (Entered: 02/10/2023) (1) |
| Feb 10, 2023 | 22 | MOTION for Pro Hac Vice Appearance of Attorney Shashank Upadhye, Yixin Tang, and Brent Batzer - filed by Nivagen Pharmaceuticals, Inc.. (Weinblatt, Richard) (Entered: 02/10/2023) (6) |
| Feb 8, 2023 | N/A | SO ORDERED re 7 MOTION to Seal Motion for Temporary Restraining Order and Preliminary Injunction. ORDERED by Judge Maryellen Noreika on 2/8/2023. (dlw) (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | N/A | SO ORDERED re 15 MOTION for Pro Hac Vice Appearance of Attorney Christina D. Brown-Marshall, Corrin N. Drakulich, Deanna J. Reichel, and Karrie Wheatley filed by Exela Pharma Sciences, LLC. ORDERED by Judge Maryellen Noreika on 2/8/2023. (dlw) (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | 16 | ORAL ORDER Setting Teleconference re 8 Motion for Temporary Restraining Order and Preliminary Injunction - IT IS HEREBY ORDERED that a Telephone Conference is set for TODAY 2/8/2023 at 04:30 PM before Judge Maryellen Noreika. As indicated in Plaintiff's 14 Letter, Plaintiff shall immediately serve this Oral Order on Defendant's registered agent in Delaware and Defendant's headquarters in California. Counsel shall provide a teleconference dial-in number and code for today's teleconference by emailing this Court's judicial administrator AND shall also serve Defendant with those credentials when serving this Oral Order. ORDERED by Judge Maryellen Noreika on 2/8/2023. (dlw) (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | N/A | Case Assigned to Judge Maryellen Noreika. Please include the initials of the Judge (MN) after the case number on all documents filed. (rjb) (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | N/A | Pro Hac Vice Attorney Deanna J. Reichel, Karrie Wheatley, Christina D. Brown-Marshall, and Corrin N. Drakulich for Exela Pharma Sciences, LLC added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | 17 | AFFIDAVIT of Service for Motion for Temporary Restraining Order and related documents served on Nivagen's California Headquarters on 2/7/2023, filed by Exela Pharma Sciences, LLC. (McCann, Douglas) (Entered: 02/08/2023) (1) |
| Feb 8, 2023 | 18 | AFFIDAVIT of Service for D.I. 16 Oral Order Setting Teleconference and dial in for 4:30 Teleconference served on Registered Agent and California Headquarters of Nivagen on 2/8/2023, filed by Exela Pharma Sciences, LLC. (McCann, Douglas) (Entered: 02/08/2023) (3) |
| Feb 8, 2023 | 19 | Letter to Honorable Maryellen Noreika from Gregory R. Booker regarding Order without notice. (Attachments: # 1 Text of Proposed Order)(Booker, Gregory) (Entered: 02/08/2023) (Main Document) (1) |
| Feb 8, 2023 | N/A | Minute Entry for proceedings held before Judge Maryellen Noreika - Telephone Conference held on 2/8/2023. Argument re 8 MOTION for Temporary Restraining Order and Preliminary Injunction. The Motion is DENIED. IT IS FURTHER ORDERED that the defendant will not launch its product for sixty (60) days from today. The parties shall follow the Court's directives regarding a briefing schedule. The transcript shall serve as the court's ruling. (Court Reporter Michele Rolfe.) (as) (Entered: 02/08/2023) (0) |
| Feb 8, 2023 | 19 | Letter to Honorable Maryellen Noreika from Gregory R. Booker regarding Order without notice. (Attachments: # 1 Text of Proposed Order)(Booker, Gregory) (Entered: 02/08/2023) (Text of Proposed Order) (2) |
| Feb 7, 2023 | 11 | SUMMONS Returned Executed by Exela Pharma Sciences, LLC.Nivagen Pharmaceuticals, Inc. served on 2/6/2023, answer due 2/27/2023. (McCann, Douglas) (Entered: 02/07/2023) (2) |
| Feb 7, 2023 | 12 | AFFIDAVIT of Service for Motion to Seal, Motion for Temporary Restraining Order, Opening Brief and Wheatley Declaration (D.I. 7 - D.I. 10) served on Registered Agent on 2/7/2023, filed by Exela Pharma Sciences, LLC. (McCann, Douglas) (Entered: 02/07/2023) (2) |
| Feb 7, 2023 | 13 | NOTICE of Appearance by Elizabeth M. Flanagan on behalf of Exela Pharma Sciences, LLC (Flanagan, Elizabeth) (Entered: 02/07/2023) (1) |
| Feb 7, 2023 | N/A | Remark: Exit electronic copies to presiding Judge on related case, MN. (smg) (Entered: 02/07/2023) (0) |
| Feb 7, 2023 | 14 | Letter to Clerk of Court from Douglas E. McCann regarding service of court papers until appearance of defendants. (McCann, Douglas) (Entered: 02/07/2023) (1) |
| Feb 7, 2023 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Christina D. Brown-Marshall, Corrin N. Drakulich, Deanna J. Reichel, and Karrie Wheatley - filed by Exela Pharma Sciences, LLC. (Booker, Gregory) (Entered: 02/07/2023) (5) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Main Document) (30) |
| Feb 6, 2023 | 2 | Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) (Entered: 02/06/2023) (3) |
| Feb 6, 2023 | 3 | Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: N/A. Date of Expiration of Patent: January 15, 2039. Thirty Month Stay Deadline: N/A. (twk) (Entered: 02/06/2023) (1) |
| Feb 6, 2023 | 4 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) USP 10,583,155; USP 11,510,941. (twk) (Entered: 02/06/2023) (1) |
| Feb 6, 2023 | 5 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parents Exela PharmSci, Inc., Exela Holdings, Inc., and Exela PharmSci Private Limited for Exela Pharma Sciences, LLC filed by Exela Pharma Sciences, LLC. (twk) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 6 | Summonses Issued (please complete the top portion of the form and print out for use/service). (twk) (Entered: 02/06/2023) (2) |
| Feb 6, 2023 | 7 | MOTION to Seal Motion for Temporary Restraining Order and Preliminary Injunction - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A)(McCann, Douglas) Modified on 2/7/2023 (dlw). (Entered: 02/06/2023) (Main Document) (4) |
| Feb 6, 2023 | 8 | MOTION for Temporary Restraining Order and Preliminary Injunction - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Text of Proposed Order)(McCann, Douglas) Modified on 2/7/2023 (dlw). (Entered: 02/06/2023) (Main Document) (3) |
| Feb 6, 2023 | 9 | [SEALED] OPENING BRIEF in Support re 8 MOTION for Temporary Restraining Order and Preliminary Injunction filed by Exela Pharma Sciences, LLC. Answering Brief/Response due date per Local Rules is 2/21/2023. (McCann, Douglas) Modified on 2/7/2023 (dlw). (Entered: 02/06/2023) (0) |
| Feb 6, 2023 | 10 | [SEALED] DECLARATION of Karrie Wheatley re 8 MOTION for Temporary Restraining Order and Preliminary Injunction, 9 Opening Brief in Support by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit 1 - Lietzan Declaration, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7 - Hartman Declaration, # 8 Exhibit 8 - Kuhn Declaration, # 9 Exhibit 9 - Koneru Declaration, # 10 Exhibit 10 - Maness Declaration, # 11 Exhibit 11, # 12 Exhibit 12)(McCann, Douglas) Modified on 2/7/2023 (dlw). (Entered: 02/06/2023) (0) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit A) (4) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit B) (10) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit C) (30) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit D) (30) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit E) (20) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit F) (13) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit G) (4) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit H) (11) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit I) (30) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit J) (27) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Exhibit K) (17) |
| Feb 6, 2023 | 1 | COMPLAINT filed with Jury Demand against Nivagen Pharmaceuticals, Inc. ( Filing fee $ 402, receipt number ADEDC-4060533.) - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C, # 4 Exhibit D, # 5 Exhibit E, # 6 Exhibit F, # 7 Exhibit G, # 8 Exhibit H, # 9 Exhibit I, # 10 Exhibit J, # 11 Exhibit K, # 12 Civil Cover Sheet)(twk) (Entered: 02/06/2023) (Civil Cover Sheet) (2) |
| Feb 6, 2023 | 7 | MOTION to Seal Motion for Temporary Restraining Order and Preliminary Injunction - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A)(McCann, Douglas) Modified on 2/7/2023 (dlw). (Entered: 02/06/2023) (Text of Proposed Order) (1) |
| Feb 6, 2023 | 7 | MOTION to Seal Motion for Temporary Restraining Order and Preliminary Injunction - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Text of Proposed Order, # 2 Exhibit A)(McCann, Douglas) Modified on 2/7/2023 (dlw). (Entered: 02/06/2023) (Exhibit A) (3) |
| Feb 6, 2023 | 8 | MOTION for Temporary Restraining Order and Preliminary Injunction - filed by Exela Pharma Sciences, LLC. (Attachments: # 1 Text of Proposed Order)(McCann, Douglas) Modified on 2/7/2023 (dlw). (Entered: 02/06/2023) (Text of Proposed Order) (2) |
